Tempus AI, Inc. (TEM) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Persistent losses ⢠High leverage TEM has solid liquidity and gross margins, but persistent losses, negative free cash flow, and high leverage make it a risky investment despite short-term balance-sheet flexibility.
Price Behavior
Key Price Behavior Insights: ⢠Breakout surge ⢠Pullback consolidation ⢠Support defense Support Level: $51â$52 Resistance Level: $55.5â$57.0 TEM has strengthened over the last month with a sharp breakout and higher lows, but the pullback from the recent peak leaves it range-bound between low-$50s support and mid/high-$50s resistance, so buyers need to defend $51 to keep the bullish setup intact.
Sentiment & News
Key News Insights: ⢠Diagnostics growth ⢠Data contract wins ⢠Profitability progress Tempus AI is showing strong momentum in diagnostics, data services, and AI oncology partnerships, with improving profitability signals, though losses and valuation concerns still remain.
AI Summary
Tempus AI has moved from a speculative growth story to a more credible scaling platform as diagnostics, data/Insights, and AI tools improve operating leverage, but the stock still depends on proof that positive EBITDA converts into durable cash flow and reimbursement-supported margin expansion rather than a temporary growth burst.
Description
Tempus AI, Inc. is a healthcare technology company that performs molecular diagnostics, including next-generation sequencing, PCR profiling, genotyping and anatomic pathology for healthcare providers, pharmaceutical and biotechnology firms, and researchers. It also licenses a de-identified, linked clinicalâmolecularâimaging dataset and offers analytics, cloud compute tools, clinical trial matching, algorithmic oncology tests and software for test ordering and research workflows. The company entered strategic collaborations with AstraZeneca and Pathos AI, was incorporated in 2015, changed its name from Tempus Labs in January 2023, and is headquartered in Chicago, Illinois.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 9 | Dec 16 | TEM | Tempus AI, Inc. | Tempus AI exhibits strong near-term growth supported by exceptional Q3 2025 results (85% revenue growth, first positive adjusted EBITDA) and strategic FDA clearances and collaborations. Despite recent price volatility and unresolved litigation risks, accelerating genomics testing and data licensing growth underline concrete short-term return potential. | Closed | -10.2% |